Previous close | 2.3800 |
Open | N/A |
Bid | 3.6000 |
Ask | 3.8000 |
Strike | 9.00 |
Expiry date | 2024-06-21 |
Day's range | 2.3800 - 2.3800 |
Contract range | N/A |
Volume | |
Open interest | 10 |
Helen Thackray, Chief Research & Development Officer of BioCryst Pharmaceuticals Inc (NASDAQ:BCRX), purchased 30,000 shares of the company on May 14, 2024.
On May 13, 2024, Steven Galson, a Director at BioCryst Pharmaceuticals Inc (NASDAQ:BCRX), purchased 21,940 shares of the company, as reported in a recent SEC Filing.
Charles Gayer, Chief Commercial Officer of BioCryst Pharmaceuticals Inc (NASDAQ:BCRX), purchased 30,000 shares of the company on May 13, 2024.